Mode
Text Size
Log in / Sign up

BiPAP improves oxygenation over HFNC in pediatric asthma exacerbation, but evidence is limitedBiPAP may offer better oxygen levels for children with asthma

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider BiPAP for better oxygenation in pediatric asthma exacerbation, but confirmatory trials are needed.

This meta-analysis evaluated high-flow nasal cannula (HFNC) versus bi-level positive airway pressure (BiPAP) in children aged 2-18 years with asthma exacerbation, including 374 patients. The primary outcome was not reported; secondary outcomes included length of hospital stay, PICU stay, and oxygenation parameters.

For length of hospital stay, there was no significant impact (MD = -0.24, 95% CI: -1.66 to 1.19). Similarly, PICU stay showed no significant difference (MD = -0.04, 95% CI: -0.82 to 0.73). For SpO and PCO, no significant differences were found. However, BiPAP significantly improved PaO and SaO compared to HFNC.

The authors noted significant heterogeneity across the four indicators and emphasized the need for confirmation in future high-quality clinical trials. Safety outcomes were not reported.

Practice relevance: Both HFNC and BiPAP can provide adequate ventilatory support, but BiPAP may offer better oxygenation. However, BiPAP's superiority in oxygenation requires confirmation in high-quality clinical trials.

How this fits prior evidence

This meta-analysis extends prior evidence on pediatric asthma management by comparing two noninvasive ventilation strategies. Prior coverage noted that TCM decoctions may improve lung function in pediatric asthma but with low certainty; the current findings provide a direct comparison of HFNC and BiPAP, showing no difference in length of stay but potential oxygenation benefit with BiPAP. This contrasts with the bidirectional associations between asthma and inflammatory bowel disease reported earlier, as the current study focuses on acute exacerbation management rather than systemic associations.

When a child struggles to breathe during an asthma flare-up, doctors must choose the best way to deliver oxygen and support their breathing. This study looked at two common methods: high-flow nasal cannula (HFNC), which delivers oxygen through a mask or tube, and bi-level positive airway pressure (BiPAP), a machine that provides both oxygen and pressure to help open airways.

The researchers looked at data from 374 children between the ages of 2 and 18. They found that while both methods provided adequate support, BiPAP showed significantly better results for oxygenation levels compared to the nasal cannula. However, neither method showed a significant difference in how long children stayed in the hospital or in the intensive care unit.

It is important to note that these findings come from a meta-analysis, which combines several different studies. Because there was a lot of variation between those original studies, experts say we still need high-quality clinical trials to confirm if BiPAP is truly superior for oxygenation. For now, both methods are recognized as effective ways to help children breathe during an asthma crisis.

What this means for you:
BiPAP may provide better oxygen levels than nasal cannulas for children with asthma, though both offer adequate support.

Common questions

Is BiPAP better than a nasal cannula for my child's asthma?

Both methods provide adequate support for breathing. However, this study of 374 children found that BiPAP significantly improved oxygenation levels compared to high-flow nasal cannulas. Because the results are based on combined data with some variation, doctors still need more high-quality trials to confirm these specific differences.

Does one treatment help kids stay in the hospital for less time?

The study found no significant difference between using a nasal cannula and BiPAP regarding the length of hospital stays or the amount of time spent in the intensive care unit (PICU). Both methods were equally effective in these specific areas for children aged 2 to 18.

What are the limitations of this finding?

The researchers noted significant differences across the data they analyzed. Because of this variation, the finding that BiPAP improves oxygenation needs to be confirmed by future high-quality clinical trials before it can be fully established as a standard.

Study Details

Study typeMeta analysis
Sample sizen = 374
EvidenceLevel 1
Follow-up216.0 mo
PublishedJul 2026
View Original Abstract ↓
OBJECTIVE: To compare the effects of high-flow nasal cannula (HFNC) and bi-level positive airway pressure (BiPAP) in the treatment of children with asthma exacerbation. METHODS: MEDLINE, Embase, CINAHL Complete, China National Knowledge Infrastructure (CNKI), and WanFang databases were systematically searched through 1 December 2024. Studies comparing HFNC and BiPAP in children aged 2-18 years with asthma exacerbation were included. Two reviewers independently screened titles, abstracts, and full texts. Randomized controlled trials (RCTs) and cohort studies reporting clinical or respiratory outcomes were eligible. RESULTS: After screening, a total of 7 studies were included, comprising 374 participants, with 5 randomized controlled trials (RCTs) and 2 retrospective cohort studies. Among the included studies, 5 reported on length of hospital stay, and 4 reported on PICU stay. Both treatment modalities showed no significant impact on hospital stay (MD = -0.24, 95% CI: -1.66, 1.19) or PICU stay (MD = -0.04, 95% CI: -0.82, 0.73). Three studies reported on PaO, while 2 studies provided data on SaO, SpO, and PCO. Significant heterogeneity was observed across the four indicators, and random-effects models were used for analysis. The results indicated no significant difference in SpO and PCO between the two treatment groups, but BiPAP significantly improved PaO and SaO compared to HFNC. CONCLUSIONS: Both HFNC and BiPAP can provide adequate ventilatory support for children with asthma exacerbation. However, BiPAP may provide benefits in greater oxygenation (PaO, SaO); this effect needs confirmation in future high-quality clinical trials.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.